Next Article in Journal
Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles and Their Potential as Novel Immunomodulatory Therapeutic Agents
Next Article in Special Issue
Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
Previous Article in Journal
The Immune Adjuvant Effects of Flounder (Paralichthys olivaceus) Interleukin-6 on E. tarda Subunit Vaccine OmpV
Previous Article in Special Issue
Immune Checkpoints as a Target for Colorectal Cancer Treatment
Open AccessArticle

Molecular and Clinicopathological Differences by Age at the Diagnosis of Colorectal Cancer

Division of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112, Taiwan
Department of Surgery, Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
Department of Clinical Pathology, Yang-Ming Branch, Taipei City Hospital, Taipei 11146, Taiwan
Division of Genomic Medicine, National Health Research Institutes, Zhunan 350, Taiwan
Department of Pathology, Taipei Veterans General Hospital, Taipei 112, Taiwan
Endoscopy Center for Diagnosis and Treatment, Taipei Veterans General Hospital, Taipei 112, Taiwan
Author to whom correspondence should be addressed.
These authors contributed equally to the manuscript.
Int. J. Mol. Sci. 2017, 18(7), 1441;
Received: 10 June 2017 / Revised: 27 June 2017 / Accepted: 28 June 2017 / Published: 5 July 2017
We compared the clinicopathological and molecular profiles between different age groups of sporadic colorectal cancer (CRC) patients (age <50, 56–60, 60–70, 70–80, and >80); 1475 CRC patients were enrolled after excluding 30 individuals with Lynch syndrome. The mutation spectra for APC, TP53, KRAS, PIK3CA, FBXW7, BRAF, NRAS, HRAS, TGFbR, Akt1, and PTEN were analyzed using polymerase chain reaction (PCR), followed by MassArray and microsatellite (MSI-high) analysis by performing genotyping. Male patients (74.1%) were significantly predominant to females (25.9%) in the older age group (70–80, >80). There was an insignificantly linear trend between TNM staging and age-onset of CRC diagnosis. Patients aged < 50 had 58.7% diseases in the advanced stages (Stage III: 36.5% and IV: 22.2% respectively), while this decreased to 40.2% (Stage III: 26.2% and IV; 14.0% respectively) in patients >80. The distributions of mutation frequency were similar in majority of the genes studied among different age groups. Additionally, patients aged <50 had significantly higher frequency of MSI-high, PTEN, and HRAS mutations than those of other groups. Age-onset at diagnosis significantly affected overall survival (HR = 1.46; 95% CI: 1.35–1.58), but not cancer-specific survival (HR = 1.08; 95% CI: 0.99–1.18) in multivariate analysis. In conclusion, molecular and clinicopathological differences were not as significant among different age groups of CRC patients as previously suspected. View Full-Text
Keywords: colorectal cancer; mutation; p53; APC; MSI; PI3K colorectal cancer; mutation; p53; APC; MSI; PI3K
Show Figures

Figure 1

MDPI and ACS Style

Chang, C.-C.; Lin, P.-C.; Lin, C.-C.; Lan, Y.-T.; Lin, H.-H.; Lin, C.-H.; Yang, S.-H.; Liang, W.-Y.; Chen, W.-S.; Jiang, J.-K.; Lin, J.-K.; Chang, S.-C. Molecular and Clinicopathological Differences by Age at the Diagnosis of Colorectal Cancer. Int. J. Mol. Sci. 2017, 18, 1441.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop